International Cancer Study & Therapy Conference
April 04-06, 2016, Baltimore, USA
Novel benzothiazole-piperazine derivatives with anticancer activity
1Yeditepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Turkey
2Department of Molecular Biology and Genetics, BilGen, Genetics and Biotechnology Research Center, Faculty of Science, Bilkent University, Turkey
3CancerSystems Biology Laboratory, Graduate School of Informatics, Middle East Technical University, Turkey
New series of benzothiazole-piperazine derivatives are synthesized and their cytotoxic activities are evaluated on colorectal (HCT-116), breast (MCF-7) and hepatocellular (HUH-7) cancer cell lines by sulforhodamine B assay. Results are compared with 5-fluorouracil as reference compound.
Dihalo substituted compounds BTP-2 (N-(6-ethoxybenzothiazole-2-yl)-2-[4-(2,6-dichlorobenzyl)piperazinyl]acetamide) (HCT-116:GI50 =0.4 µM; HUH-7: GI50 =0.7 µM; MCF-7: GI50 =2.6 µM) and BTP-7 (N-(6-ethoxybenzothiazole-2-yl)-2-[4-(4-bromo-2-fluorobenzyl)piperazinyl]acetamide)(HCT-116:GI50 =0.9 µM; HUH-7: GI50 =0.3 µM; MCF-7: GI50 =12.2 µM) are found to have highest cytotoxic activities in all studied cancer cell lines.
Professor Yarim has completed his Ph.D from Hacettepe University and postdoctoral studies from ETH-Zürich. Professor Yarim has studied anticancer drug design and she has authored several peer-reviewed reports. She has served on numerous review committees for the National Science Foundation in Turkey. She has served on the editorial boards for the Pharmacologia. She is a member of the QSAR Society.